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FOR THE ROMEO INVESTIGATORS
OBJECTIVE — A trial was performed to establish whether our group care model for lifestyle
intervention in type 2 diabetes can be exported to other clinics.
RESEARCH DESIGN AND METHODS — This study was a 4-year, two-armed, multi-
center controlled trial in 13 hospital-based diabetes clinics in Italy (current controlled trials no.
ISRCTN19509463). A total of 815 non–insulin-treated patients aged 80 years with 1 year
known diabetes duration were randomized to either group or individual care.
RESULTS — After 4 years, patients in group care had lower A1C, total cholesterol, LDL
cholesterol, triglycerides, systolic and diastolic blood pressure, BMI, and serum creatinine and
higher HDL cholesterol (P  0.001, for all) than control subjects receiving individual care,
despite similar pharmacological prescriptions. Health behaviors, quality of life, and knowledge
ofdiabeteshadbecomebetteringroupcarepatientsthanincontrolsubjects(P0.001,forall).
CONCLUSIONS — The favorable clinical, cognitive, and psychological outcomes of group
care can be reproduced in different clinical settings.
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L
ifestyle intervention reduces inci-
dence of (1,2) and helps improve
metabolic control in (3,4) type 2 di-
abetes. However, lifestyle advice given
during individual consultations remains
secondary to pharmacological interven-
tion (5). We developed a model to deliver
diabetescareasgroupeducationsessions,
which improves clinical outcomes, pa-
tients’qualityoflife(QoL),andclinicians’
satisfaction while optimizing use of the
typically limited resources of busy clinics
(6–8).
TheRethinkOrganizationtoiMprove
Education and Outcomes (ROMEO) trial
was a multicenter trial (9) aimed at eval-
uating if setting and results of group care
can be reproduced in other clinics.
RESEARCH DESIGN AND
METHODS— A total of 815 patients
with non–insulin-treated type 2 diabetes of
1 year known duration, aged 80 years,
wererandomizedtoeithergroup(casesub-
jects) or traditional one-to-one (control
subjects) care (online appendix Fig. 1
[available at http://care.diabetesjournals.
org/cgi/content/full/dc09-2024/DC1]).
Patients from 13 hospital-based clinics
gave their informed consent (online ap-
pendix Table 1). ROMEO was approved
by the ethics committee of the coordinat-
ing center in Turin. Power calculations
indicated that 550 patients would allow
to detect a decrease in A1C from 8.0 to
7.5%, with an 0.05 and 0.05.
Randomization was done locally by ran-
dom table numbers.
Body weight, fasting glycemia, blood
pressure,andA1Cweremeasuredevery3
months. Creatinine, total and HDL cho-
lesterol, and triglycerides were measured
yearly. LDL cholesterol was calculated by
Friedewald’s formula (10). Health behav-
iors (Condotte di Riferimento  CdR) (8)
and QoL (11) were measured by previ-
ously described speciﬁc questionnaires at
baseline and years 2 and 4. Knowledge of
diabetes (12) was measured at baseline
and year 4 by the Italian Study Group for
Diabetes Education (Gruppo Italiano di
Studio Educazione e Diabete [GISED]).
Group care sessions and individual
visits were every 3 months by the same
operators. The approach and curriculum
weredescribedpreviously(6–8).Inbrief,
seven 1-h sessions were held over 2 years
and repeated. Education involved mainly
groupwork,hands-onactivities,problem
solving, real-life simulations, and role
playing (online appendix 2). All patients
received individual consultations at least
yearly, whenever deemed necessary by
operators, or upon request.
Trialinvestigatorsweretrainedinour
laboratory on principles of adult educa-
tion and analysis of the intervention pro-
gram and were supported in transferring
group care to their clinics. Operating
manual (available in an online appendix),
teachingmaterials,logisticalsupport,and
supervision were provided throughout
the study. Individual visits remained
based upon local clinical practice.
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scriptive data are shown as absolute fre-
quencies if categorical and means  SD if
continuous variables. Differences between
groups at baseline were checked by 
2 or t
testforindependentdata,asapplicable.Dif-
ferences between baseline and year 4 were
tested by t test for dependent data.
Results are expressed as differences
and 95% CI between treatment groups.
Differencesbetweencaseandcontrolsub-
jects were adjusted for center, sex, family
history for diabetes, schooling, occupa-
tion, years of attendance in clinic, and
baseline values of the dependent variable.
The different frequencies of patients
reaching clinical targets at baseline and
year 4 were tested by the McNemar test
forpairedsamples.Oddsratiosofbeingat
target at year 4 being a case rather than a
control subject were estimated by a mul-
tivariate logistic model adjusted for age,
sex, duration of diabetes, family history,
andbaselinevaluefortheconsideredvari-
able. Differences were considered signiﬁ-
cant for P  0.05.
RESULTS— Two clinics did not com-
pletethetrial.Case(n106)andcontrol
(n  128) dropouts had similar baseline
variables. In the case subjects, BMI, fast-
ing glycemia, A1C, total cholesterol, trig-
lycerides, LDL cholesterol, and systolic
and diastolic blood pressure decreased
from baseline to year 4, while HDL cho-
lesterol increased (P  0.001, for all) and
creatinine did not change (online appen-
dix Table 2). BMI, A1C, triglycerides, and
creatinine increased in control subjects,
whereas total, HDL, and LDL cholesterol
and systolic blood pressure did not
change and diastolic blood pressure de-
creased. At study end, case subjects had
higher HDL cholesterol (1.42  0.29 vs.
1.29  0.33 mmol/l) and lower A1C
(7.3  0.9 vs. 8.8  1.2%), fasting glyce-
mia (8.78  2.27 vs. 9.44  2.89 mg/dl),
total cholesterol (4.88  0.96 vs. 5.47 
0,94 mmol/l), LDL cholesterol (2.79 
0.94 vs. 3.31  0,97 mmol/l), triglycer-
ides (1.46  0.59 vs. 1.94  1.17 mmol/
l), systolic blood pressure (138.0  16.1
vs. 143.6  18.5 mmHg), diastolic blood
pressure (79.1  9.4 vs. 80.6  8.4
mmHg), body weight (80.4  14.6 vs.
82.1 kg), BMI (30.1  5.0 vs. 30.4  5.8
kg/m
2), and creatinine (76.0  23.0 vs.
85.7  26.5 mmol/l) than control sub-
jects (P  0.001, for all).
Health behaviors, QoL, and knowl-
edge improved in case subjects (P 
0.001, for all). Health behaviors did not
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and knowledge worsened. At study end,
health behaviors (15.24  2.62 vs.
11.07  3.00), QoL (63.22  10.27 vs.
77.88  13.14), and knowledge
(48.37  13.42 vs. 38.69  14.07) were
betterinthecasesubjects(P0.001,all).
The proportion of cases with A1C
7.0%, systolic pressure 130 mmHg,
diastolic pressure 80 mmHg, and LDL
cholesterol 2.58 mmol/l (100 mg/dl) at
year 4 increased from baseline, and those
who met all targets doubled (Table 1).
Controlsubjectsremainedstableorwors-
ened. Prescriptions of hypoglycemic, an-
tihypertensive, and lipid-lowering
medications were similar for case and
control subjects. A total of 50 of 315 case
subjects (15.87%) and 56 of 266 control
subjects (21.05%) were on insulin at
study end.
CONCLUSIONS — Lifestyle inter-
vention requires delivery of continuing
patient education and care without in-
creasing clinical workload and with mea-
surable outcomes. In our experience,
reorganizing working practice as rou-
tinely delivered group care is a feasible
and cost-effective approach to improve
metabolic control and QoL in type 2 dia-
betes (6–8).
ROMEO, a multicenter controlled
trial, showed that group care is transfer-
able and conﬁrmed its efﬁcacy. A1C and
lipids improved and, at study end, the
share of case subjects achieving currently
recommended clinical targets (5) in-
creased from baseline, the opposite being
true for control subjects. That improve-
ment occurred without additional medi-
cation strongly suggests that healthier
behaviors were induced by group care.
As the acronym ROMEO suggests,
group care requires reallocation of tasks,
roles, and resources and a change in pro-
viders’ attitudes from the traditional pre-
scriptive approach to a more empathic
role of facilitator. This may limit its trans-
ferability, as one clinic did not start the
trial and another withdrew after 2 years.
Previous studies of education in dia-
betes management varied in approach,
were shorter, and measured less out-
comes (13,14). The Diabetes Education
and Self-Management for Ongoing and
Newly Diagnosed (DESMOND), the only
other multicenter trial of education in
type 2 diabetes, did not register improve-
ments in A1C or QoL over a 1-year fol-
low-up in newly diagnosed patients (15).
Continuing interactive patient-centered
education by group care is reproducible
and improves diabetes management and
outcomes.
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